{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:31:44Z","timestamp":1759624304036,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":546,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.exphem.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T10:42:38Z","timestamp":1628937758000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA\/BURKIMAB\/PETHEMA LAL"],"prefix":"10.1016","volume":"101-102","author":[{"given":"Alberto","family":"Mar\u00edn-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Mart\u00ednez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"G\u00f3mez-Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari Carmen","family":"Montoya-Morcillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Lorenzo","family":"Algarra-Algarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela","family":"Iba\u00f1ez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Hern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ram\u00f3n","family":"Romero-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Manual Pr\u00e1ctico de Hematolog\u00eda Cl\u00ednica","author":"Sanz","key":"10.1016\/j.exphem.2021.08.003_bib0001"},{"key":"10.1016\/j.exphem.2021.08.003_bib0002","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab\u2013hyper-CVAD alternating with rituximab\u2013high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0003","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood.V118.21.2698.2698","article-title":"Hyper-CVAD and rituximab for de novo Burkitt lymphoma\/leukemia","volume":"118","author":"Thomas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.08.003_bib0004","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.exphem.2021.08.003_bib0005","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.exphem.2021.08.003_bib0006","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.08.003_bib0008","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2021.08.003_bib0011","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0012","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0013","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.08.003_bib0014","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia Study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0015","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0016","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2008.201","article-title":"Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma","volume":"42","author":"Murali","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2021.08.003_bib0017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000492531","article-title":"Comparison between hyper-CVAD and PETHEMA ALL-93 in adult acute lymphoblastic leukemia: a single-center study","volume":"63","author":"Erkut","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.exphem.2021.08.003_bib0018","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1002\/cncr.32156","article-title":"Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 Trial from the Spanish PETHEMA Group","volume":"125","author":"Ribera","year":"2019","journal-title":"Cancer"},{"year":"2017","series-title":"Pautas de quimioterapia en hemopat\u00edas malignas","author":"Ribera","key":"10.1016\/j.exphem.2021.08.003_bib0019"},{"key":"10.1016\/j.exphem.2021.08.003_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ejh.13178","article-title":"Increased Survival due to lower toxicity for high risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials","volume":"102","author":"Barba","year":"2019","journal-title":"Eur J Hematol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0021","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.08.003_bib0022","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1002\/cncr.25319","article-title":"Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen","volume":"116","author":"Thomas","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2021.08.003_bib0023","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/10428194.2018.1482541","article-title":"Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET\/CT in adult Burkitt's lymphoma: the role of Deauville and IHP Criteria","volume":"60","author":"Albano","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2021.08.003_bib0024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjh.12744","article-title":"Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia","volume":"165","author":"Della Starza","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2021.08.003_bib0025","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2021.08.003_bib0026","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.08.003_bib0027","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","article-title":"Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2021.08.003_bib0028","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2021.08.003_bib0029","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2021.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X21002836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X21002836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:36:08Z","timestamp":1759566968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X21002836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"alternative-id":["S0301472X21002836"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2021.08.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA\/BURKIMAB\/PETHEMA LAL","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}